Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.
Document Type
Article
Publication Date
10-8-2015
Institution/Department
Pediatrics
Journal Title
Blood.
MeSH Headings
Biomarkers, Child, Cohort Studies, Dexamethasone, Female, Follow-Up Studies, Genetic Predisposition to Disease, Genome-Wide Association Study, Glucocorticoids, Humans, Male, Meta-Analysis as Topic, Neoplasm Staging, Osteonecrosis, Polymorphism, Single Nucleotide, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Receptors, N-Methyl-D-Aspartate, Risk Factors
Abstract
Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors for osteonecrosis. We performed a genome-wide association study of single nucleotide polymorphisms (SNPs) in a discovery cohort comprising 2285 children with ALL, treated on the Children's Oncology Group AALL0232 protocol (NCT00075725), adjusting for covariates. The minor allele at SNP rs10989692 (near the glutamate receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio = 2.03; P = 3.59 × 10(-7)). The association was supported by 2 replication cohorts, including 361 children with ALL on St. Jude's Total XV protocol (NCT00137111) and 309 non-ALL patients from Vanderbilt University's BioVU repository treated with glucocorticoids (odds ratio [OR] = 1.87 and 2.26; P = .063 and .0074, respectively). In a meta-analysis, rs10989692 was also highest ranked (P = 2.68 × 10(-8)), and the glutamate pathway was the top ranked pathway (P = 9.8 × 10(-4)). Osteonecrosis-associated glutamate receptor variants were also associated with other vascular phenotypes including cerebral ischemia (OR = 1.64; P = 2.5 × 10(-3)), and arterial embolism and thrombosis (OR = 1.88; P = 4.2 × 10(-3)). In conclusion, osteonecrosis was associated with inherited variations near glutamate receptor genes. Further understanding this association may allow interventions to decrease osteonecrosis. These trials are registered at www.clinicaltrials.gov as #NCT00075725 and #NCT00137111.
ISSN
1528-0020
First Page
1770
Last Page
1776
Recommended Citation
Karol, Seth E; Yang, Wenjian; Van Driest, Sara L; Chang, Tamara Y; Kaste, Sue; Bowton, Erica; Basford, Melissa; Bastarache, Lisa; Roden, Dan M; Denny, Joshua C; Larsen, Eric; Winick, Naomi; Carroll, William L; Cheng, Cheng; Pei, Deqing; Fernandez, Christian A; Liu, Chengcheng; Smith, Colton; Loh, Mignon L; Raetz, Elizabeth A; Hunger, Stephen P; Scheet, Paul; Jeha, Sima; Pui, Ching-Hon; Evans, William E; Devidas, Meenakshi; Mattano, Leonard A; and Relling, Mary V, "Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia." (2015). Maine Medical Center. 839.
https://knowledgeconnection.mainehealth.org/mmc/839
